Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy by Chand, Deepa et al.








Hepatotoxicity following administration of onasemnogene abeparvovec
(AVXS-101) for the treatment of spinal muscular atrophy
Chand, Deepa ; Mohr, Franziska ; McMillan, Hugh ; Tukov, Francis Fonyuy ; Montgomery, Kyle ;
Kleyn, Aaron ; Sun, Rui ; Tauscher-Wisniewski, Sitra ; Kaufmann, Petra ; Kullak-Ublick, Gerd
Abstract: Background aims: Spinal muscular atrophy (SMA) is an autosomal recessive, childhood-onset
motor neuron disease. Onasemnogene abeparvovec (OA) is a gene therapy designed to address SMA’s
root cause. In pivotal mouse toxicology studies, the liver was identified as a major site of OA toxicity.
Clinical data reflect elevations in serum aminotransferase concentrations, with some reports of serious
acute liver injury. Prophylactic prednisolone mitigates these effects. Herein, we aim to provide pragmatic,
supportive guidance for identification, management, and risk mitigation of potential drug-induced liver
injury. Methods: Data from 325 patients with SMA who had received OA through 31 December 2019, in
5 clinical trials, a managed access program (MAP), and a long-term registry (RESTORE), and through
commercial use, were analyzed. Liver-related adverse events, laboratory data, concomitant medications,
and prednisolone use were analyzed. Results: Based on adverse events and laboratory data, 90 of 100
patients had elevated liver function test results (alanine aminotransferase, and/or aspartate aminotrans-
ferase, and/or bilirubin concentrations). Of these, liver-associated adverse events were reported for 34 of
100 (34%) and 10 of 43 (23%) patients in clinical trials and MAP/RESTORE, respectively. Two patients
in MAP had serious acute liver injury, which resolved completely. While all events in the overall popu-
lation resolved, prednisolone treatment duration varied (range: 33-229 days), with a majority receiving
prednisolone for 60-120 days. More than 60% had elevations in either alanine aminotransferase, aspar-
tate aminotransferase, or bilirubin concentrations prior to dosing. Greater than 40% received potentially
hepatotoxic concomitant medications. Conclusions: Hepatotoxicity is a known risk associated with OA
use. Practitioners should identify contributing factors and mitigate risk through appropriate monitor-
ing and intervention. Lay summary: Onasemnogene abeparvovec is a type of medicine called a ”gene
therapy,” which is used to treat babies and young children who have a rare, serious inherited condition
called ”spinal muscular atrophy” (SMA). It works by supplying a fully functioning copy of the survival
motor neuron or SMN gene, which then helps the body produce enough SMN protein. However, it can
cause an immune response that could lead to an increase in enzymes produced by the liver. This article
provides information about the liver injury and how to prevent and recognize if it happens, so that it
may be treated properly.
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 Onasemnogene abeparvovec is an approved gene therapy for spinal
muscular atrophy.
 Hepatotoxicity is a known risk associated with onasemnogene
abeparvovec.
 Liver-related data for 325 patients who received onasemnogene
abeparvovec were analyzed and are presented.
 The risk of hepatotoxicity can be serious if not recognized.
 Practitioners should mitigate risk through appropriate monitoring
and intervention.
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Onasemnogene abeparvovec is a
type of medicine called a “gene
therapy,” which is used to treat
babies and young children who
have a rare, serious inherited con-
dition called “spinal muscular
atrophy” (SMA). It works by sup-
plying a fully functioning copy of
the survival motor neuron or SMN
gene, which then helps the body
produce enough SMN protein.
However, it can cause an immune
response that could lead to an in-
crease in enzymes produced by the
liver. This article provides informa-
tion about the liver injury and how
to prevent and recognize if it hap-
pens, so that it may be treated
properly.
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Background & Aims: Spinal muscular atrophy (SMA) is an
autosomal recessive, childhood-onset motor neuron disease.
Onasemnogene abeparvovec (OA) is a gene therapy designed to
address SMA's root cause. In pivotal mouse toxicology studies,
the liver was identified as a major site of OA toxicity. Clinical data
reflect elevations in serum aminotransferase concentrations,
with some reports of serious acute liver injury. Prophylactic
prednisolone mitigates these effects. Herein, we aim to provide
pragmatic, supportive guidance for identification, management,
and risk mitigation of potential drug-induced liver injury.
Methods: Data from 325 patients with SMA who had received
OA through 31 December 2019, in 5 clinical trials, a managed
access program (MAP), and a long-term registry (RESTORE), and
through commercial use, were analyzed. Liver-related adverse
events, laboratory data, concomitant medications, and prednis-
olone use were analyzed.
Results: Based on adverse events and laboratory data, 90 of 100
patients had elevated liver function test results (alanine amino-
transferase, and/or aspartate aminotransferase, and/or bilirubin
concentrations). Of these, liver-associated adverse events were
reported for 34 of 100 (34%) and 10 of 43 (23%) patients in
clinical trials and MAP/RESTORE, respectively. Two patients in
MAP had serious acute liver injury, which resolved completely.
While all events in the overall population resolved, prednisolone
treatment duration varied (range: 33–229 days), with a majority
receiving prednisolone for 60–120 days. More than 60% had el-
evations in either alanine aminotransferase, aspartate amino-
transferase, or bilirubin concentrations prior to dosing. Greater
than 40% received potentially hepatotoxic concomitant
medications.
Conclusions: Hepatotoxicity is a known risk associated with OA
use. Practitioners should identify contributing factors and miti-
gate risk through appropriate monitoring and intervention.
Lay summary: Onasemnogene abeparvovec is a type of medicine
called a “gene therapy,” which is used to treat babies and young
children who have a rare, serious inherited condition called
“spinal muscular atrophy” (SMA). It works by supplying a fully
functioning copy of the survival motor neuron or SMN gene,
which then helps the body produce enough SMN protein.
However, it can cause an immune response that could lead to an
increase in enzymes produced by the liver. This article provides
information about the liver injury and how to prevent and
recognize if it happens, so that it may be treated properly.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive, early
childhood disease with an incidence of approximately 1:10,000
live births.1–3 The genetic diagnosis of SMA is based on the
presence of a survival motor neuron 1 or SMN1 mutation or
deletion. Phenotype was historically classified into 4 groups
based on age at onset and greatest motor function achieved,
with an additional phenotype (type 0) to describe the severe
forms of antenatal onset.4 Approximately 45–60% of cases have
the most common phenotype, SMA type 1. Phenotype severity is
largely determined by SMN2 copy numbers, with a minor
contribution from other genetic or environmental factors. In-
dividuals born with 0 to 3 copies of SMN2 in the presence of a
bi-allelic SMN1 deletion or mutation have a high probability of
developing a severe phenotype.4 Prior to the availability of
effective treatment, SMA was the leading genetic cause of infant
mortality.1,5
SMA is a motor neuron disease whose root cause is SMN
protein deficiency.6 Deficiency of this protein correlates directly
with motor neuron death, resulting in the progressive loss of
muscle control, strength and function, thereby leading to diffi-
culty swallowing and breathing and, consequently, to death.7
Although the primary pathology of SMA is neuronal, clinical
reports indicate involvement of other organs, including the liver,
heart, pancreas, and intestine.8 SMA has been associated with
impaired hepatic function, with more than one-third of
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autopsies of children with SMA revealing liver steatosis on post-
mortem necropsy.
Zolgensma® (onasemnogene abeparvovec) has been
approved for the treatment of SMA in the United States, Europe,
Japan, Brazil, Israel, Canada, and Taiwan. Onasemnogene abe-
parvovec is a single-dose, intravenous gene therapy designed to
address the monogenic root cause of SMA by utilizing a non-
replicating, non-integrating, recombinant adeno-associated vi-
rus serotype 9 (AAV9) capsid to deliver a stable, fully functional
human SMN transgene to increase SMN protein expression and
prevent motor neuron cell death, leading to improved neuronal
and muscular function. The SMN present in onasemnogene
abeparvovec resides as a DNA episome in the nucleus of trans-
duced cells, and appears to be highly stable in post-mitotic cells,
such as motor neurons.
Clinical trials have demonstrated clear evidence of clinically
meaningful efficacy following administration of onasemnogene
abeparvovec in this otherwise devastating, neurodegenerative
disease. Transient elevations in serum aminotransferase con-
centrations have been reported following the use of onasemno-
gene abeparvovec, although the exact mechanism of injury has
not been elucidated. Preclinical studies have suggested an im-
mune response to the vector capsid as a possible mechanism.
Cell-mediated immunity directed against the AAV capsid plays
an important role in safety and efficacy of AAV gene transfer in
humans. Immune responses have been observed in AAV vector
clinical trials across different neuromuscular diseases (e.g., SMA,
Duchenne muscular dystrophy, myotubular myopathy). Trans-
duction and subsequent expression of the AAV vector in fixed
tissue macrophages in the liver, known as Kupffer cells, can elicit
an immune response and effectively eliminate the therapeutic
effect by developing antibodies to the capsid and/or transgene or
eliminating the transduced cells through a cytotoxic T-cell-
mediated mechanism.9 Generation of capsid-specific T-cell
responses may depend on the AAV serotype used, and the
specificity of the AAV capsid variants may impact immune
recognition.10 Once a certain threshold of capsid antigen load has
been reached, activation of capsid-specific T cells may result in
hepatotoxicity in some cases.11,12 Anti-capsid cytotoxic T-cell-
mediated destruction of transduced hepatocytes in the clinical
setting may be mitigated with prophylactic or on-demand
immunosuppression. No immunosuppressive regimens were
used in preclinical studies with onasemnogene abeparvovec.
Herein, we describe these liver effects, paying particular
attention to clinical characteristics, with the aim of providing
pragmatic, supportive guidance for the identification, manage-




The data on liver abnormalities were from 2 basic sources: (1) 5
sponsored clinical trials of open-label treatment (summarized in
the supplementary information) and (2) compassionate use and
post-marketing data monitored by the sponsor. The data
collected in the clinical trials were prospective and specified via
protocol. Data from the compassionate use and post-marketing
studies were ad hoc (i.e., reported voluntarily to the company).
In the latter situation, attempts were made to obtain additional
details from the reporting sources.
Clinical trials
All studies were performed in accordance with ethical principles
from the Declaration of Helsinki and are consistent with Inter-
national Council for Harmonisation/Good Clinical Practice and
applicable regulatory requirements. All study protocols were
approved by the institutional review boards and appropriate
informed consent was obtained.
As of 31 December 2019, 101 patients in 5 clinical studies (2
completed and 3 ongoing) had received a single intravenous
dose of onasemnogene abeparvovec (Table S1). Studies were
registered with www.clinicaltrials.gov (START: NCT02122952,
STR1VE-US: NCT03306277, SPR1NT: NCT03505099, STR1VE-EU:
NCT03461289, and STR1VE-AP: NCT03837184). Study data were
not available within this data cut-off for STR1VE-AP, and,
therefore, the number of patients dosed for this analysis
was 100.
Patients were eligible to participate if they had been geneti-
cally diagnosed with SMA type 1 and were <8 months of age
(<180 days; or <
−
6 weeks for the pre-symptomatic SPR1NT) at the
time of infusion.
Patients were excluded from clinical study participation if
they had elevated (either >3 or >2× the upper limit of normal
[ULN], depending on the protocol) baseline gamma-
glutamyltransferase, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), or total bilirubin values; anti-AAV9
antibody titer >1:50; prior or concomitant SMA-treating medi-
cations (e.g., nusinersen); or known allergy or hypersensitivity to
glucocorticoids.
Eligible patients received a 1-time intravenous dose of ona-
semnogene abeparvovec. With the exception of the first 3 pa-
tients who received a lower dose in the Phase I START study, all
other patients received the therapeutic dose of 1.1 × 1014 vg/kg in
the START, STR1VE-US, SPR1NT, and STR1VE-EU studies. For
analytic purposes, all patients dosed were evaluated. Prophy-
lactic administration of prednisolone was outlined in study
protocols. Patients received approximately 1 mg/kg/day of
prednisolone (or equivalent) 24 hours prior to dosing through at
least 30 days post-administration. A recommended tapering
schedule was provided in protocols, including guidelines for
adjustment based on elevations in serum aminotransferase
concentrations. In March 2019, in response to a report of acute
liver failure, this prednisolone dosing schedule was revised. The
revised regimen included initiation at 2 mg/kg/day, starting the
day prior to dosing, for 3 days; and then reduction to 1 mg/kg/
day for 30 days, with tapering. Modification to dosing and
duration of glucocorticoids was left to the investigators'
discretion.
Per study protocols, safety was assessed through reported
adverse events, vital signs, cardiac and laboratory evaluations
(chemistry, hematology, urinalysis, and immunology), physical
examinations, and concomitant medications. Specifically, hepa-
totoxicity was evaluated using a combination of adverse events
coded in accordance with Medical Dictionary of Regulatory Ac-
tivities (MedDRA®; Version 21.0), and scheduled interval labo-
ratory values. With standard nomenclature, adverse events were
classified as serious if they met applicable criteria.13 Serum
aminotransferase concentrations were also evaluated using Hy's
Law criteria.14 Per protocol, serum antibody titers to AAV9 were
collected and analyzed. Specific, pre-determined terms were
used to systematically search for investigator-reported liver-
related adverse events indicative of potential hepatotoxicity. To
2 Journal of Hepatology 2020 vol. - j 1–7
Research Article DILI, Autoimmune, Cholestatic and Genetic Diseases
comprehensively evaluate hepatotoxicity, we also evaluated
laboratory data to assess abnormal values not reported as
adverse events.
Study inclusion criteria excluded patients with mild baseline
elevations. For the purpose of this current analysis, the number
(%) of patients meeting the following predefined potential hep-
atotoxicity criteria was summarized as ALT and/or AST: i) >
−
3×
ULN to <5× ULN (mild); ii) >
−





Under special circumstances (i.e., compassionate use), treatment
with onasemnogene abeparvovec was initiated by physician
request in the United States for patients with SMA type 1 older
than 6 months of age. This initially occurred in the setting of an
individual investigational new drug (IND) application held by
individual physicians, and subsequently through a managed
access program (MAP) protocol. The MAP terminated upon
approval of onasemnogene abeparvovec by the US FDA on 24
May 2019.
The Prospective, Long-Term Registry of Patients with a Diag-
nosis of Spinal Muscular Atrophy (RESTORE) was initiated on 24
May 2018. It is an ongoing, global, observational registry
designed to assess long-term outcomes, safety, and effectiveness
of onasemnogene abeparvovec. Some patients in this registry
received SMA treatment other than onasemnogene abeparvovec
and are excluded from this analysis.
Post-marketing data
After approval of onasemnogene abeparvovec in respective re-
gions, safety data continues to be monitored through various
avenues including spontaneous reports, literature, solicited
venues, etc. Safety was assessed through reported adverse
events. Each reported adverse event within the Hepatobiliary
Disorders system organ class was reviewed.
Statistical methods
Summary statistics for continuous data, including ALT, AST, and
prednisolone, were analyzed as mean, standard deviation, me-
dian, minimum, and maximum. Plots were generated and sta-
tistical analyses were performed using SAS® 9.4 statistical
software to assess the magnitude and duration of elevations in
serum aminotransferase concentrations. These were plotted with
respect to interval AAV9 antibody titers. Patient visit windows
were applied per study protocols. All data were descriptive; no
a priori hypothesis tests are provided.
Results
Clinical studies
Overall, 101 patients were enrolled into intravenous studies, of
whom 100 were included in this analysis. Only 1 patient was
enrolled in STR1VE-AP at the time of data cut-off; this patient
was excluded from this analysis as a full clinical analysis of
STR1VE-AP was unavailable. Of note, this patient continues in the
study and has not had reported liver-associated adverse events
or elevated serum aminotransferase concentrations. De-
mographics and clinical characteristics of the 100 patients
analyzed are summarized in Table S2. Mean age for therapeutic
dosing was 2.9 months, and 59% of patients were female. SPR1NT
enrolled only pre-symptomatic patients, thereby representing a
younger patient population (mean age = 0.8 months).
Medical history and concomitant medications
At least 1 comorbid conditionwas reported for 53 of 100 patients
(53%). The most common comorbidities were gastroesophageal
reflux disease (12%), hypotonia (12%), atrial septal defect (9%),
and eczema (5%). All other conditions were reported in <5% of
patients.
Concomitant medications were defined as any medication
started on or after the date of onasemnogene abeparvovec
administration and were updated at each visit. Overall, 96 of 100
clinical study patients (96%) reported the use of at least 1
concomitant medication. The most commonly used concomitant
medications were acetaminophen (>40%), ibuprofen (>20%), and
ranitidine (>20%).
Concomitant medication data were not collected in RESTORE
or MAP, as they represent clinical practice. Similarly, post-
marketing data were primarily from spontaneous self-
reporting, and information on concomitant medication was
often missing. Therefore, results cannot be provided for these
sources.
Prednisolone exposure
Ninety-nine of 100 patients received prophylactic prednisolone
following a protocol revision after increased serum transaminase
concentrations occurred in the first patient dosed in START, the
initial phase I study.
As prednisolone treatment duration was at the discretion of
the investigators, mean duration of prednisolone treatment was
83 days (range: 33–229) in all the studies, with a majority of
patients receiving prednisolone for 60–120 days (Fig. 1, Table S3).
As a result of this variability in dosage and duration, no corre-
lation between prednisolone dosage and magnitude and
duration of increases/decreases in serum aminotransferase con-
centrations were assessable.
Adverse event overview
Of the 100 patients who received intravenous onasemnogene
abeparvovec, 99 experienced at least 1 adverse event after
dosing. Of these, 57 (57%) were considered by the investigator to
have been related to onasemnogene abeparvovec. Moreover, 48
patients experienced serious adverse events, of which 11 were
considered by the investigator to have been related to ona-
semnogene abeparvovec. The most frequently reported
treatment-related adverse events and serious adverse events
across all studies were elevations in serum aminotransferase
enzyme concentrations and vomiting.
Liver-specific evaluation
Of patients who received therapeutic intravenous dosing, 34
(34%) had at least 1 adverse event within the hepatotoxicity
category. All adverse events associated with increased serum
aminotransferases concentrations resolved completely, some
with alterations in prednisolone dosing.
In analyzing laboratory data, we included any elevation after
dosing, irrespective of baseline value. Of 100 children treated in
clinical trials, 90% had at least some degree of ALT and/or AST
elevation during therapy. While the majority of elevations were
<3× ULN, 9% were categorized as mild (>
−
3× ULN to < 5× ULN), 6%
as moderate (>
−
5 to <20× ULN), and 5% as severe (>
−
20× ULN)
(Table S4). No patient had elevations in ALT and/or AST concen-
trations, with concurrent elevations in bilirubin >
−
2× ULN in
clinical trials. The elevations typically began at Week 1 after the
Journal of Hepatology 2020 vol. - j 1–7 3
infusion with a second peak at Month 1, at the time of the
tapering and discontinuation of systemic corticosteroid therapy.
Individual patient data with respect to onset and resolution days,
outcomes, and respective prednisolone dosing in those with
moderate to severe elevations are depicted in Table S5.
Of note, 61 patients (61%) had elevations in ALT and/or AST
and/or bilirubin concentrations prior to dosing. In the SPR1NT
trial, 23 of 30 (76.7%) pre-symptomatic patients had elevations in
ALT and/or AST and/or bilirubin concentrations at baseline prior
to dosing that were less than study exclusion thresholds, all of
which normalized over time and remained normal at final study
visit.
As of 31 December 2019, no clinical trial cases meeting clin-
ical or biochemical criteria for Hy's law were observed.
The relationship between serum aminotransferases concen-
tration elevations and anti-AAV9 antibody titers was explored.
Elevations in serum aminotransferase concentrations, if present,
were observed following antibody titer increases. As expected in
all cases, antibody concentrations increased after onasemnogene
abeparvovec administration and remained elevated and stable
through data cut-off, irrespective of serum aminotransferase
normalization. A schematic of the typical rise and fall in anti-AAV
antibodies and serum aminotransferase concentrations for an
individual patient representing a majority of the study patients is
provided in Fig. 2.
Open-access programs
As of 31 December 2019, 54 patients were enrolled in US MAP
and/or RESTORE combined: 11 of whom did not receive ona-
semnogene abeparvovec and were excluded from this analysis.
Of the 43 patients dosed with onasemnogene abeparvovec, 28
patients (65.1%) experienced adverse events, and 13 patients
(30.2%) experienced serious adverse events. The most frequently
reported treatment-related adverse events included ALT and/or
AST concentration increases for 10 patients (23.3%); liver func-
tion test increases for 5 patients (11.6%; 4 of these overlap with
ALT and/or AST increases); thrombocytopenia for 4 patients
(9.3%); and vomiting for 2 patients (4.7%).
In many cases, neither concomitant use of prednisolone nor
dosage were reported. However, the transaminase elevations
resolved completely in all cases. Only 2 children (4.7%) devel-
oped concurrent bilirubin elevations, arising with severe
elevations in ALT and AST (>40× ULN). Presenting bilirubin con-
centrations were 8.4 and 3.5 mg/dl and INR values were 6.6 and
1.5, respectively. Both children responded to re-initiation of
prednisone therapy or dosage increase and ultimately could be
withdrawn from immunosuppressive therapy without recur-
rence of hepatitis. Details on the 2 cases of liver injury reported
in the MAP are presented in the supplementary information.
Post-marketing safety cases
As data from the compassionate use and post-marketing studies
were not collected in a structured manner, but rather provided
unilaterally by the reporter, specific details (e.g., peak laboratory
values, time to resolution, concomitant medications, etc.) were
inconsistent and limited. As of 31 December 2019, 181 patients
had received onasemnogene abeparvovec commercially, and 192
reports of 488 adverse events were retrieved from the Novartis
Global Patient Safety database. Individual patients often had
multiple reports and events at various time points. Most events
contained limited information regarding concomitant medica-
tions, outcome, medical history, etc. The most frequently re-
ported events included pyrexia (50), vomiting (42), hepatic
enzyme increased (24), AST increased (23), ALT increased (19),
liver function test increased (17), platelet decreased (16),
troponin increased (7), thrombocytopenia (7), cough (7), naso-
pharyngitis (7), and weight decreased (6).
Discussion
The term SMA is applied to a diverse group of genetic disorders,
of which the most common form results from bi-allelic muta-
tions in the SMN1 gene on chromosome 5q13.2,15 A deletion or
mutation of both copies of SMN1 results in decreased expression
of the SMN protein.16 The SMN2 copy number is inversely related
to the phenotypic continuum of clinical severity. A greater
number of copies is associated with less severe disease.17,18
Childrenwith SMA have been reported to have abnormal fatty
acid metabolism, which was reported to cause liver failure in a
patient with SMA type 2, who required orthotopic liver trans-
plant.19 The authors attributed the sensitivities to abnormal b-
oxidation (e.g., dicarboxylic aciduria) which appeared to be
unique to SMA compared with non-SMA denervating disorders,
and correlated with clinical severity, as infants with severe SMA
have significant abnormalities in concentrations of fatty acid
metabolites. Similarly, Brehm et al.20 reported on a patient with
SMA and liver injury after receiving therapeutic doses of acet-
aminophen. They postulated that patients with decreased mus-
cle mass were susceptible to acetaminophen toxicity because of
decreased stores of glutathione, as well as reduced volume of
distribution, thus leading to increased plasma acetaminophen
concentrations.20 In addition, more than one-third of autopsies
of children with SMA exhibited evidence of liver steatosis.20
While non-alcoholic steatohepatitis is a diagnostic consider-
ation for adult patients with acute liver injury, non-alcoholic
steatohepatitis is extremely rare in very young children.21
In pivotal toxicology studies of neonatal FVB/NJ mice, the liver
was identified as one of the main sites of onasemnogene abe-
parvovec toxicity. Liver findings were noted at doses above the
clinical recommended intravenous dose of 1.1 × 1014 vg/kg ona-
semnogene abeparvovec. Increases in serum aminotransferase
(ALT, AST) concentrations were noted at 3, 6, and/or 12 weeks
post intravenous injection, with evidence of reversibility by
Week 12. These transient elevations in serum aminotransferase






























Fig. 1. Distribution of prednisolone duration in onasemnogene abeparvo-
vec clinical studies.
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concentrations were suggestive of hepatocellular damage and
correlated with histopathology findings composed of hepato-
cellular hypertrophy, Kupffer cell activation, and scattered he-
patocellular necrosis. In a recently published study, a single
intravenous injection of 2.0 × 1014 vg/kg of an AAV9-like vector
(AAVhu68) carrying the SMN transgene to juvenile rhesus ma-
caques, resulted in significant systemic inflammation and liver
toxicity including transaminase elevations.22 The mechanism of
onasemnogene abeparvovec–related liver damage is unknown,
but given the liver is among the most transduced tissues, these
liver effects are likely associated with hepatocellular uptake of
AAV.
Two patients (see supplementary information) also described
by Feldman AG et al.,23 met the diagnostic criteria for DILI, but
not solely for drug-induced liver failure because of confounding
factors (e.g., pre-existing elevations and family history in Case 1,
and lack of jaundice, encephalopathy, or impairment of liver
synthetic function in Case 2). Both patients were treated with
methylprednisolone and were discharged from the hospital
within 2 weeks of initial diagnosis. Both patients underwent
biopsy and exhibited inflammatory infiltrates composed of CD8+
T cells (Case 1 in the periportal areas and Case 2 as mild interface
hepatitis). Case 1 had fibrosis on biopsy; repeat liver biopsy
performed 2 months later revealed resolution of inflammation
but persistence of fibrosis. Serum aminotransferase concentra-
tions had normalized at the time of repeat biopsy, raising the
question of pre-existing liver disease.
Pre-existing liver enzyme elevations, especially in SMA chil-
dren, may represent underlying liver disease, a predisposition to
acute liver injury.19 Clinical norms should be based on age-
appropriate limits, rather than laboratory defined reference
ranges. Based on the combination of adverse event and labora-
tory data, 90 of 100 patients had some degree of elevations in
ALT and/or AST and/or bilirubin concentrations, and 61 (61%) had
elevations in ALT and/or AST and/or bilirubin concentrations,
prior to dosing. Of the pre-symptomatic study patients, 23
(76.7%) had some degree of elevations in ALT and/or AST and/or
bilirubin concentrations at baseline, which raises the possibility
of underlying liver abnormalities. Despite these baseline eleva-
tions, the prevalence and causality of inherent liver dysfunction
in patients with SMA are unknown. Serum AST and bilirubin
concentrations must be interpreted carefully during infancy as
physiologic changes can be misinterpreted as liver injury.24
Although the primary feature of SMA is neurodegeneration,
some clinical reports indicate that other organs are involved,
including the liver, heart, pancreas, and intestine, some of which
may contribute to enzymatic release.8 Red blood cells contain
AST25 and the increased turnover because of physiologic transi-
tion from fetal to adult hemoglobin may cause AST concentra-
tions to be up to 6-fold greater for infants than for adults.26,27
Should patients have elevations in aminotransferase concentra-
tions and/or signs of biliary disease prior to dosing, practitioners
should consider potential etiologies based on clinical presenta-
tion, signs and symptoms, age, and medical and family histories.
Darras et al.28 and Feldman et al.23 have described serum
aminotransferase concentration elevations with nusinersen
administration and the combination of onasemnogene abe-
parvovec with nusinersen administration within 1 month,
respectively. Nusinersen is an antisense oligonucleotide, which
increases production of full-length SMN protein by modifying
splicing in available SMN2 pre-mRNA, and is given via repeat








































































































Fig. 2. AAV antibody titer concentrations compared with liver function test values for average patient representative of population. Y-axis retains same
scale through entire study by patient. The axis is not reset for each graphing internal. Y2-axis is on a linear scale (not Log Base 2 scale). Each dilution on the Y2-
axis is double the preceding dilution. Patients' titer results are included within the plot. A <1:50 titer is considered as negative. AAV9, adeno-associated virus
serotype 9; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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hepatotoxic medications should be avoided if possible, before
administration of onasemnogene abeparvovec and within 1
month after dosing, as liver enzyme elevations have been mainly
described within 1 month after dosing with onasemnogene
abeparvovec.
In the 5 clinical studies, the transient increases in mean ALT
and AST values occurred at approximately Day 7, with a return to
near baseline concentrations at approximately Day 14. Second
transient increases in mean ALT and AST values were observed at
Month 1, with return to near baseline concentrations by Month 2
(supplementary information). All serum aminotransferase con-
centration elevations normalized by the end of the study
observation periods. While commercial use of the product
confirmed this temporal relationship, actual laboratory values
with respect to time to resolution were often not provided in this
setting.
Given the mechanism of hepatotoxicity is presumed to be
immune-mediated, prednisolone was used empirically in the
first patient dosed to treat aminotransferase transaminase con-
centrations to complete resolution. Since then, it has been used
prophylactically in all clinical trial patients and is recommended
to be used with onasemnogene abeparvovec administration as
standard of care. In the clinical trials, investigators were allowed
to use discretion with prednisolone dosing and duration based
on their clinical judgments for each individual patient. Liver
histopathology was not obtained in the clinical trials and pre-
clinical studies have not been conducted to evaluate the effects
of prednisolone in this setting. Hence, no conclusive recom-
mendations can be made on optimal prednisolone dosage or
duration in response to aminotransferase concentration
elevations.
In summary, hepatotoxicity related to onasemnogene abe-
parvovec use typically presents as non-cholestatic (i.e., as ele-
vations in serum aminotransferases concentrations). Some
children have presented with elevations as high >20× ULN in ALT
and/or AST, most often occurring at 1 week and 1 month after
onasemnogene abeparvovec dosing. This should be anticipated.
Accordingly, any potential contributors including underlying
disease state and hepatotoxic concomitant medications should
be appropriately investigated and avoided if possible. Predniso-
lone should be used prophylactically in accordance with pre-
scribing guidelines and greater dosages and/or longer duration
considered in the setting of post-dose elevations in serum
aminotransferase concentrations. Consultation with a pediatric
gastroenterologist/hepatologist should be considered as clini-
cally appropriate. A summary of hepatotoxicity associated with
onasemnogene abeparvovec use in SMA patients is presented in
Fig. 3.
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